Biosensors Int'l, Terumo, will market Nobori stent in Japan

Terumo's Nobori drug-eluting stent--courtesy of Terumo

Biosensors International will work with Japan's Terumo to promote that company's Nobori drug-eluting stent in Japan. They'll focus on specific specialist cardiology centers in a deal that begins in April and is designed to last at least three years. It also makes practical sense. That's because Nobori already uses Biosensors' technology in two ways--the Bioliumus A9 drug and an abluminal biodegradable polymer coating. The companies are fast friends, essentially; before their co-promotion deal they renewed their technology licensing agreement at least through 2014. Release